# Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

> **NCT04485104** · PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Seizure in Participants With Tuberous Sclerosis Complex
- Seizure in Participants With Dravet Syndrome
- Seizure in Participants With Lennox-Gastaut Syndrome

## Interventions

- **DRUG:** GWP42003-P

## Key facts

- **NCT ID:** NCT04485104
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-19
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-01-28
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated by the Sponsor due to low patient enrollment.
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485104, "Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04485104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*